MS2-Affinity Purification Coupled with RNA Sequencing in Gram-Positive Bacteria
February 23rd, 2021
MAPS technology has been developed to scrutinize the targetome of a specific regulatory RNA in vivo. The sRNA of interest is tagged with a MS2 aptamer enabling the co-purification of its RNA partners and their identification by RNA sequencing. This modified protocol is particularly suited for Gram-positive bacteria.
MS2-affinity purification coupled with RNA sequencing or MAPS has been developed to identify the whole targetome of any RNA of interest in bacteria. This technology makes it possible to identify any kind of sRNA partners independently of the mechanism of regulation. The characterization of sRNA-dependent regulatory networks will help understand better virulence factors production, biofilm formation, and survival of the bacteria within the host cells, and ultimately fight against staphylococcal infections.
This protocol can be applied to any pathogenic or non-pathogenic gram-positive bacteria. Demonstrating the procedure will be Noemie Mercier, a PhD student from Dr.Pascal Romby's laboratory. To begin, grow one colony of strains carrying either pCN51 P3 MS2 sRNA or pCN51 P3 MS2 plasmids in three milliliters of BHI medium supplemented with 10 micrograms per microliter erythromycin in duplicates.
Dilute each overnight culture in 50 milliliters of fresh BHI medium supplemented with erythromycin to reach an OD 600 of 0.05. Grow the cultures at 37 degrees Celsius with shaking at 180 RPM for six hours. Transfer each culture into a 50 milliliter centrifuge tube and centrifuge the tubes at 2, 900 times G for 15 minutes at four degrees Celsius, then discard the supernatant, freeze and store them at minus 80 degrees Celsius or keep the pellets on ice and directly perform mechanical cell lysis.
To perform mechanical cell lysis, resuspend pellets in five milliliters of buffer A and transfer the resuspended cells to 15 milliliter centrifuge tubes with 3.5 grams of silica beads. Insert the tubes in a mechanical cell lysis instrument and run a cycle of 40 seconds at four meters per second. Centrifuge the tubes at 2, 900 times G for 15 minutes, then recover the supernatant and keep it on ice.
Make sure that the supernatant is clear, repeating the centrifugation if it is not. Remove the column tip, then put a chromatography column in a column rack and wash the column with ultrapure water. Add 300 microliters of amylose resin and wash the column with 10 milliliters of buffer A.Dilute 1, 200 picamoles of MBP-MS2 protein in six milliliters of buffer A and load it into the column.
Wash the column with 10 milliliters of buffer A.Next, perform MS2-affinity purification. Load the cell lysate into the column and collect the flow-through fraction in a clean collection tube. Wash the column three times with 10 milliliters of buffer A and collect the wash fraction, then elute the column with one milliliter of buffer E and collect the elution fraction in a two milliliter microtube.
Keep all collected fractions on ice until RNA extraction. Use one milliliter of each fraction for RNA extraction. Add one volume of phenol to the RNA and mix vigorously, then centrifuge the mixture at 16, 000 times G for 10 minutes at 20 degrees Celsius.
Transfer the upper phase to a clean two milliliter microtube. Add one volume of chloroform isoamyl alcohol and repeat the centrifugation, then transfer the upper phase to a new tube. Add 2.5 volumes of 100%cold ethanol and 0.1 volume of three molar sodium acetate at pH 5.2 and precipitate overnight at minus 20 degrees Celsius.
On the next day, centrifuge the tubes for 15 minutes at 16, 000 times G and four degrees Celsius. Slowly remove the ethanol with a pipette, taking care not to disturb the pellet. Add 500 microliters of 80%cold ethanol and centrifuge for five minutes.
Discard the ethanol by pipetting it slowly, then dry the pellet using a vacuum concentrator for five minutes on run mode. Resuspend the pellet in an appropriate volume of ultrapure water. This protocol was used to study the RsaC targetome in S.aureus.
Several mRNAs interacting directly with RsaC were identified using MAPS technology, revealing its crucial role in oxidative stress and metal-related responses. To confirm the MS2 sRNA constructs and visualize their pattern of expression, cells were harvested after two, four, and six hours of growth in BHI medium. RNA was extracted and Northern blot analysis was performed using the RsaC-specific DIG probe.
The level of endogenous RsaC significantly increased after six hours of growth. Importantly, the level of MS2-RsaC 544 and MS2-RsaC 1, 116 were comparable to endogenous RsaC at six hours. Affinity purification was performed and RNAs were extracted from the crude extract, flow-through, and elution fractions in the wild-type strain expressing the MS2 tag alone and the mutant RsaC strain expressing the MS2-RsaC 544 construct.
The 1, 116 nucleotide long endogenous RsaC was enriched in the elution fraction, but interacted non-specifically with the affinity column due to its length and complex secondary structure. The MS2-RsaC 544 was highly enriched in the elution fraction demonstrating that it was successfully retained by the MS2-MBP fusion protein. A bioinformatic analysis revealed putative mRNA targets according to the fold change between MS2 sRNA and MS2 control, indicating that sodA was the first putative target.
A Northern blot analysis performed sodA-specific DIG probe after MS2-affinity purification shows that sodA was efficiently co-enriched with MS2-RsaC 544 compared to the MS2 control. When attempting this protocol, keep in mind that the addition of the MS2 tag can affect sRNA confirmation, stability, or function. This should be carefully monitored.
MAPS provides a snapshot of sRNA-RNA targets pairing. Further experimental validation will unravel their function. This technique represents a powerful tool to build sRNA regulatory networks in any bacteria.
View the full transcript and gain access to thousands of scientific videos
Overview
MAPS technology enables the identification of the targetome of specific regulatory RNAs in vivo, particularly in Gram-positive bacteria. This method utilizes MS2-affinity purification and RNA sequencing to co-purify and identify RNA partners.
Key Study Components
Area of Science
- Neuroscience
- Microbiology
- RNA Biology
Background
- Understanding sRNA-dependent regulatory networks is crucial for studying bacterial behavior.
- Identifying RNA partners can shed light on virulence factors and biofilm formation.
- MAPS technology allows for independent identification of sRNA partners.
- This protocol is applicable to both pathogenic and non-pathogenic Gram-positive bacteria.
Purpose of Study
- To characterize sRNA-dependent regulatory networks in bacteria.
- To enhance understanding of bacterial survival mechanisms within host cells.
- To develop strategies against staphylococcal infections.
Methods Used
- MS2-affinity purification coupled with RNA sequencing.
- Growth of bacterial strains in BHI medium with erythromycin.
- Co-purification of sRNA and its partners for analysis.
- Identification of RNA partners through sequencing techniques.
Main Results
- Successful identification of sRNA partners in Gram-positive bacteria.
- Insights into regulatory networks affecting virulence and survival.
- Demonstration of the protocol by a PhD student from Dr. Pascal Romby's lab.
- Potential applications in combating bacterial infections.
Conclusions
- MAPS technology is a powerful tool for studying RNA interactions.
- Understanding sRNA networks can lead to better therapeutic strategies.
- This method can be adapted for various bacterial species.
Frequently Asked Questions
Executive Industry Relevance
MAPS technology enables comprehensive targetome mapping of small regulatory RNAs in Gram-positive pathogens, supporting target validation in antimicrobial discovery. By revealing sRNA-mRNA interactions that influence virulence and survival, it provides mechanistic de-risking for early-stage antibacterial programs. This approach enhances predictive confidence in prioritizing sRNA targets for therapeutic intervention.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of sRNA-dependent regulatory networks to clarify therapeutic hypotheses in Gram-positive bacteria.
- Operational Value: Provides a snapshot of sRNA targetomes to support biological de-risking and functional target validation.
- Scientific Value: Identifies putative mRNA targets such as sodA, linking sRNA activity to oxidative stress and metal response pathways.
Screening & Assay Development
- Scientific Value: Generates quantitative RNA sequencing outputs from co-purified fractions to enable reproducible target identification.
- Operational Value: Standardizes capture via MS2-MBP fusion on amylose resin, supporting assay scalability across Gram-positive strains.
- Scientific Value: Delivers enrichment metrics (e.g., elution fraction) to distinguish specific from non-specific RNA interactions.
Translational & Preclinical Research
- Scientific Value: Connects sRNA regulons to phenotypic outputs like virulence factor production and biofilm formation in Staphylococcus aureus.
- Operational Value: Supports translational biomarker alignment by linking sRNA activity to stress response pathways relevant to infection.
- Scientific Value: Facilitates risk-adjusted advancement decisions by validating sRNA targets through orthogonal methods like Northern blot.
Pipeline & Workflow Integration
MAPS fits within the discovery continuum from target identification to lead optimization, particularly for antibacterial programs targeting RNA-based regulation.
- Discovery Biology: Supports hypothesis testing of sRNA function by mapping RNA interactomes in vivo under defined growth conditions.
- Screening: Enables assay readiness through standardized lysis, affinity capture, and RNA extraction workflows compatible with sequencing.
- Analytics: Provides fold-change measurements between MS2-sRNA and control fractions to prioritize high-confidence targets for follow-up.
- Translational Research: Links sRNA targetomes to host survival mechanisms, informing preclinical validation of anti-infective strategies.
- Enterprise Reuse: Establishes a reusable platform for sRNA targetome profiling across pathogenic and non-pathogenic Gram-positive species.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in sRNA target identification, reduction of mechanistic ambiguity in post-transcriptional regulation.
- Operational Value: Standardization, reproducibility, and scalability of RNA-protein interaction capture in bacterial lysates.
- Strategic Value: Better go/no-go decisions in antimicrobial target selection, capital efficiency, and reduced late-stage biological risk.
- Portfolio Impact: Risk-adjusted prioritization of sRNA targets based on enrichment data and phenotypic correlation.
Implementation Considerations
- Requires expertise in molecular cloning, bacterial culture, and RNA handling.
- Needs mechanical lysis infrastructure, chromatography systems, and RNA sequencing capabilities.
- Demands cross-team standardization for construct design (e.g., MS2-sRNA fusions) and expression validation.
- Requires adaptation considerations for sRNA stability and secondary structure when applying to diverse Gram-positive models.
- Practical limitation: Putative targets require orthogonal validation (e.g., Northern blot) to confirm specificity due to potential non-specific interactions.
